Early Avastin management in acute retinal vein occlusion

(A) OCT of a case of CRVO at baseline with ↑ CRT and sponge like CME; (B) OCT of the same case after 3 (IVA) injections with marked resolution of CME; (C) OCT of the same case at the end of follow-up (successful treatment).

(A) OCT of a case of superior temporal BRVO at baseline with CME; (B) OCT of the same case after two IVA injections (6months); (C) OCT of the same case at the end of follow-up (successful treatment).

(A) Lt., inferior temporal BRVO, red free fundus photography; (B) Lt., inferior temporal BRVO, FA showing Fl. dye leakage of ME; (C) Lt., inferior temporal BRVO, red free same case 6months after IVA injection; (D) Lt., inferior temporal BRVO, FA, same case 6months after IVA injection; (E) OCT, of the same case at baseline showing ↑ CMT due to CME; (F) OCT, with initial resolution of CME and ↓ CMT 1week of IVA injection; (G) OCT showing recurrence of CME 6months after first injection; (H) OCT of the same case at the end of follow-up with successful resolution of CME.

(A) Fundus photography and FA of a case of Lt., superior macular BRVO showing retinal Hge, cotton wool spots, exudates and surface wrinkling maculopathy seen next day of occlusion.

(A) FA, of Lt., upper temporal BRVO at baseline; (B) OCT of the same case with ME and ↑ CRT at baseline; (C) FA, of the same case 1month after first IVA injection (↓ ME and retinal hemorrhage); (D) OCT of the same case with resolution of ME and ↓ CRT at 1month after first IVA injection.

The mean CRT in μm measured with OCT.

Visual acuity in logMAR in over time.

BCVA improvement with follow-up time.